APA (7th ed.) Citation

Wharton, S., le Roux, C. W., Bozkurt, B., Platz, E., Bleckert, G., Ajaz Hussain, S., . . . Kaplan, L. M. (2025). Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes. Diabetes, obesity and metabolism. https://doi.org/10.1111/dom.70263

Chicago Style (17th ed.) Citation

Wharton, Sean, et al. "Baseline Characteristics in the SYNCHRONIZE-2 Randomized Phase 3 Trial of Survodutide, a Glucagon Receptor/GLP-1 Receptor Dual Agonist, for Obesity in People with Type 2 Diabetes." Diabetes, Obesity and Metabolism 2025. https://doi.org/10.1111/dom.70263.

MLA (9th ed.) Citation

Wharton, Sean, et al. "Baseline Characteristics in the SYNCHRONIZE-2 Randomized Phase 3 Trial of Survodutide, a Glucagon Receptor/GLP-1 Receptor Dual Agonist, for Obesity in People with Type 2 Diabetes." Diabetes, Obesity and Metabolism, 2025, https://doi.org/10.1111/dom.70263.